A Model For Other Cancers
The pilot has already caught the eye of patient organisations internationally. Its an interesting project, tackling the persistent problem of getting top-notch care to cancer patients in the periphery, says Bettina Ryll, founder of Melanoma Patient Network Europe. It supports local oncologists with diagnostics and expertise, so patients can receive highly specialised care close to home. It is set up in collaboration with payers and integrates research into routine clinical care. From an advocates perspective, Im obviously interested to see how patients can access and use their own data, and how the overall dataset is used to drive research. As a cancer patient, you want as many smart brains working on your problems as possible.
As a cancer patient, you want as many smart brains working on your problems as possible
Healthcare professionals are interested too. Silke Gillessen, Senior Consultant in the Department of Oncology and Haematology at the Kantonsspital St. Gallen in Switzerland, and a specialist in advanced prostate cancer, likes the early signs. It is a very good approach, in my eyes, to bring urologists into the university network and to propose therapy studies if a patient seems eligible.
We are already working on extending it to bladder cancer, the next biggest cancer in urology
Why Is Lutetium 177 Used For Psma Therapy In Prostate Cancer
PSMA is a protein found on prostate gland cells. However, when an individual has prostate cancer, the amount of PSMA on the surface of prostate cancer cells increases substantially. Lutetium-177 is the name of the radioactive medicine used in PSMA therapy, to specifically target the PSMA proteins in the body.
177Lu-PSMA-617 complex consists of 2 main components, i.e. a PSMA targeting ligand and a therapeutic radioactive atom, i.e. Lutetium-177. The Lu-177 is attached to the ligand and once the complex enters the bloodstream it gets attached to the PSMA receptor protein at the cancer cell, where Lu-177 directly damages the DNA of the cell by emitting small amounts of Beta-radiation.
This type of radiation therapy is known as radionuclide therapy, radioligand therapy, and molecular radiotherapy.
Lu-177 is the most commonly used radioactive material in targeted radiation therapy. It is preferred because it emits a lower energy of beta waves and has a shorter emission range of 1.6mm, compared to other radionuclides like Y-90. This means it can cause much less damage to the healthy tissues surrounding the cancer cells.
How Is Prostate Cancer Diagnosed
The non-invasive form of digital-rectal examination by an experienced examiner is an excellent way of detecting prostate cancer at an early stage. The prostate cancer shows a very typical palpation finding. A more precise determination of size and location is possible in a transrectal ultrasound. A special ultrasound probe is inserted rectally, and tumors with a diameter of 20 millimeters or more can be reliably detected.
A more sophisticated form of examination is the possibility of magnetic resonance imaging . In the field of nuclear medicine, positron emission tomography is now available. In this procedure, cancer cells are radioactively marked and can then be reliably defined from healthy or inflamed prostate tissue in a computer tomogram.
Among others, the prostate-specific antigen can be verified in the blood. PSA is only found in prostate tissue but is not specific for a tumor disease. The PSA level can also be elevated in an enlarged prostate gland or inflammation of the prostate . PSA is, however, a good indicator as progression parameter over the years of prostate observation and an important laboratory value in tumor aftercare (a renewed increase in PSA is a sign of tumor relapse.
The tumor prognosis depends mainly on the degree of tumor cell aggressiveness, the PSA value, the lymph node metastases, and distant metastases. As long as the tumor has not spread, there is a good chance of healing prostate cancer.
Don’t Miss: Does Radiation Make You Lose Weight
Prognosis: What Are The Healing Chances For Prostate Cancer
The prognosis for prostate cancer is relatively good. If the tumor has spread only to the prostate, life expectancy is hardly reduced.
The overall mortality rate in patients with prostate cancer is estimated at 20%. 5 years after the diagnosis of a tumor limited to the organ, 80-99% of patients are still alive. With metastatic prostate cancer, 31% are still alive after five years. The chances of recovery are only possible if the tumor is limited to the prostate.
What Are The Success Rates Of A Lutetium Treatment
PSMA therapy for prostate cancer is designed to help individuals with metastatic prostate cancer to live longer by slowing the growth of cancer cells. It is not a cure, but can help prolong the life of people with advanced prostate cancer.
The therapy showed promise in the VISION clinical trial – a large, international phase 3 study of 831 PSMA-positive patients. The results of this trial were published in the New England Journal of Medicine in September 2021. According to Dr. Michael Morris from the Memorial Sloan Kettering Cancer Center and one of the principal investigators in the trial, patients who received Lu 177 together with standard treatment had an improved survival of 38%. The men undergoing the therapy also experienced a 60% reduction in the risk of disease progression compared to the standard of care1.
This type of targeted radioligand therapy is considered an improvement over standard treatment methods. In conventional radiotherapy, doctors manually focus radiation onto regions of the body where cancer cells are located. However, in Lu 177-type targeted radiotherapy, the drug can impact the prostate cancer cells in the body, with less damage to healthy tissues. This type of treatment can also result in fewer side effects.
Recommended Reading: Best Gifts For Someone Going Through Chemo
Most Accurate Imaging Technique For Prostate Cancer Detection
Contrary to other imaging techniques MRI provides multiple mutually independent parameters for the assessment of the prostate:
- T1- and T2-relaxation time
- Tissue perfusion and
- Spectroscopic information about metabolism.
Due to this, MRI is superior to other imaging techniques such as ultrasound and also when compared to elastography.
The four pillars of multi-modal MRI diagnostics of prostate cancer: Imaging, diffusion, perfusion and spectroscopy.
Also the analysis of the chemical composition of prostatic tissue makes the diagnostic with MSR so precise and valuable.
Prostate spectroscopy depicts the chemical make-up of prostatic cells. Healthy cells contain large amounts of citrate and little cholin. Cancer cells contain less citrate, which is metabolised for the generation of energy, and more cholin, which is needed for the assembly of the cell membranes in the tumour cells.
Traitement Du Cancer De La Prostate
Il existe différentes options de traitement du cancer de la prostate. C’est avec votre médecin que vous déciderez quel est le meilleur traitement du cancer de la prostate pour vous. Le traitement comprend généralement la chirurgie et la radiothérapie pour le cancer de la prostate. Les autres options comprennent la chimiothérapie et l’hormonothérapie pour le cancer de la prostate, qui visent toutes deux à tuer les cellules cancéreuses.
Don’t Miss: Icd10 History Of Breast Cancer
Nanoknife Is A Pioneering Treatment For Prostate Cancer The First Nerve Sparing Prostate Cancer Treatment
Unlike traditional prostate cancer treatments, NanoKnife kills the prostate cancer cells instead of removing or irradiating the entire prostate. Its a one time two hour procedure, at most. Not weeks. Not months. Youre clear in days, with no side effects no incontinence, no impotence.*
Talk to us here at Vitus and youre talking to the worlds leading experts in using NanoKnife for treating prostate cancer, with over 1000 mentreated successfully.
*No incontinence in any of the patients we have treated with NanoKnife. No impotence in 90-95%.
New Therapy For Aggressive Prostate Cancer Improves Survival
The experimental treatment relies on radioactive molecules that seek out tumor cells, a strategy that may be useful against other cancers.
Send any friend a story
As a subscriber, you have 10 gift articles to give each month. Anyone can read what you share.
Give this article
- Read in app
An experimental therapy has prolonged life in men with aggressive prostate cancer that has resisted other treatments, offering new hope to patients with advanced illness and opening the door to a promising new form of cancer therapy.
Among men who received the new therapy, there was a nearly 40 percent reduction in deaths over the course of the clinical trial, compared with similar patients who received only standard treatment, researchers reported on Wednesday.
Prostate cancer is the second-leading cause of cancer death among American men, after lung cancer an estimated 34,130 men will die of prostate cancer this year. One in eight men will be diagnosed with the disease at some point in their lives. The risk increases with age, and the cancer is more common in Black men.
The new treatment relies on a radioactive molecule to target a protein found on the surface of prostate cancer cells. The study, which followed 831 patients with advanced disease in 10 countries for a median period of 20 months, was published in The New England Journal of Medicine.
You May Like: Deodorant That Doesn’t Cause Breast Cancer
A New Treatment For Advanced Prostate Cancer Improves Survival In Phase 3 Clinical Trial
- By Charlie Schmidt, Editor, Harvard Medical School Annual Report on Prostate Diseases
Radiation therapy is getting more precise, enabled by technologies that make it easier to kill tumors while sparing their surrounding tissues. Some newer therapies are even given intravenously instead of by machines, and they deliver radiation particles directly to the cancer cell itself. One of these new therapies a sort of smart bomb targeted at malignant cells is now generating promising data for men with the most aggressive prostate cancer.
In early June, investigators reported results from a phase 3 clinical trial showing that among men who received the experimental treatment, there was nearly a 40% reduction in deaths over the course of the study, compared to men who did not.
The treatment is called lutetium-177-PSMA-617, or LuPSMA, and it has two components: a compound that targets a cancer cell protein called prostate-specific membrane antigen, or PSMA, and a radioactive particle that destroys the cells. Healthy prostate cells don’t contain PSMA, or do at very low levels. And some men with prostate cancer have more of the protein than others. Doctors can detect the protein using a specialized imaging scan.
Results after 21 months showed that cancer progression was delayed for longer among the LuPSMA-treated men: 8.7 months on average versus 3.4 months among the controls. The treatment was also associated with better overall survival: 15.3 months versus 11.3 months.
The Prostate Increases In Size Over Time
The prostate is a small, walnut sized gland that sits in front of the rectum and just below the bladder. This gland produces the fluid that carries sperm through the urethra , weak or interrupted flow, pain or burning when urinating and low back pain. In most cases, early prostate cancer causes no symptoms.
According to the American Cancer Society, prostate cancer is the second most common malignancy in men in the US, and the second highest killer. Over 200,000 men in the US were diagnosed with prostate cancer in 2007. In this country, all men have a 16% chance of being diagnosed and a 3% chance of dying from this disease. Chances increase if a father or brother has had the disease. Prostate cancer is more common in African American men and the least common in Hispanic, Asian, Pacific Islanders and Native Americans.
Recommended Reading: Chemo Drugs For Ovarian Cancer
Why Choose Qunomedical For Your International Medical Needs
Millions of Americans travel to other countries for their medical needs each year. There are many reasons why.
One factor is that treatment may cost less in other countries compared to the United States. This may be a more significant driving factor in recent years, as almost 5.4 million Americans lost their health insurance during the Coronavirus pandemic a record high.
Many people also seek procedures or therapies first approved in other countries before becoming available in the United States.
Planning for medical treatment abroad can be difficult. How do you know where to start? Where do you find qualified medical professionals that fit your medical needs? How do you manage hospital stays, pricing, and travel plans while you may be suffering from pain, fatigue, and other issues?
Founded by a medical professional, Qunomedical offers a concierge approach to high-quality and affordable medical treatments abroad. Every month, we connect over 6,500 patients with professionally-vetted doctors around the world. We offer 24/7 personalized support and everything you need to make an informed decision. Get your free assessment here.
Effets Secondaires Du Traitement Du Cancer De La Prostate
Il est utile d’en savoir plus sur les effets secondaires du traitement dès le départ, afin de savoir à quoi s’attendre. Votre médecin traitant de la prostate peut en discuter avec vous et vous aider à gérer votre bien-être pendant et après le traitement. Tout le monde ne réagit pas de la même manière au traitement et les effets secondaires sont ressentis différemment. Parlez toujours à votre professionnel de la santé des effets indésirables que vous pouvez ressentir, tels que les troubles de l’érection, les douleurs, les nausées, la fatigue, l’incontinence et les changements corporels qui affectent votre sentiment d’identité.
Recommended Reading: How To Save Eyebrows During Chemo
A Smart Bomb For Prostate Cancer
After decades of research, scientists inch closer to FDA approval for PSMA-targeted treatments that show promise for patients with an advanced form of prostate cancer.
In the fall of 2016, Dr. Mark DeAntonio learned he had a mass on his bladder. Doctors suspected stage 4 bladder cancer, and they confirmed the diagnosis with a biopsy. Over the next year, DeAntonio participated in two rounds of intensive chemotherapy, but the cancer didnt regress it spread. Thats when doctors referred him to the University of Southern California to participate in a clinical trial.
It turns out, DeAntonio didnt have bladder cancer after all. The tumor developed at the end of the prostate near the bladder, where it busted through the bladder wall, says DeAntonio, now 67. It was prostate cancer all along.
Prostate cancer is the second most common cancer among men, affecting nearly 250,000 Americans annually. It happens most often when men have reached the height of their careers and are heading toward retirement and its often highly treatable when diagnosed early. But for 10% to 20% of patients like DeAntonio, the disease can spread throughout the body and be remarkably resistant to treatment, especially the most common initial therapy used androgen deprivation therapy . Called metastatic castration-resistant prostate cancer , these cancers grow and spread even in the absence of their preferred fuel: testosterone.
The cancer was growing.
What Lies Ahead: Leading The Way With Alpha Therapies
The coming years will see even more powerful forms of radioactive therapy. The MSK laboratory of radiochemist Jason Lewis and other researchers are investigating the use of alpha particles, which have a much higher energy hundreds of times more potent than the photons used in conventional radiation or beta particles. Not only do alpha particles cause more damage when they slam into cancer cells but their path of destruction is more tightly focused, sparing normal cells.
MSK is building one of the nations first dedicated alpha particle GMP labs at a U.S. academic institution.
These radiopharmaceuticals that we are creating translate very well from bench to bedside, says Dr. Lewis, Chief of the Radiochemistry and Imaging Sciences Service and Director of the Radiochemistry and Molecular Imaging Probe Core Facility. When you see these striking responses to treatment, it brings real hope for the future and our patients.
Advances in radiotheranostics are supported by The Tow Foundation, long-time contributors to MSKs mission.
- A new FDA-approved drug could be an effective treatment against prostate cancer that has spread.
- The treatment uses a molecule that seeks out and attaches to a specific protein on the cancer cell surface called PSMA
- The technology delivers radiation that damages DNA and destroys the cancer cell..
You May Like: How Long Does Radiation Last In An Area
Fda Approval For Targeted Radioligand Therapy For Treatment Of Metastatic Prostate Cancer
On March 23, 2022, the U.S. Food and Drug Administration granted approval to the first targeted radioligand therapy against metastatic prostate cancer based on a joint patent of the German Cancer Research Center and the University of Heidelberg. The agent significantly improves the chances of survival for those affected. The invention is an outstanding example of the transfer of excellent research results into clinical application, said Michael Baumann, Chairman and Scientific Director of the DKFZ.
The compound Lutetium-177 PSMA-617 was approved in the U.S. for the treatment of metastatic prostate cancer carrying the surface molecule PSMA . Approval of the drug, marketed by Novartis, is limited to patients who have received prior chemotherapy and who do not respond to hormone deprivation.
The compound had been developed in years of interdisciplinary translational research by scientists at DKFZ, Heidelberg University and Heidelberg University Hospital.
In the pivotal study , which was conducted at several U.S. hospitals, lutetium-177 PSMA-617 in combination with standard therapy reduced all-cause mortality by 38 percent and disease progression by 60 percent of subjects during the study observation period.
What Are Treatment Options For Prostate Cancer In Germany
Prostate cancer is treated with various methods, such as:
- Radical surgery for removal of the prostate gland for a localized process that does not spread beyond the organ
- Hormone therapy
- Lutetium treatment
Regimens of prostate cancer treatment are chosen by the doctor individually, with an ultimate goal of maximum impact on the malignant process with minimal side effects. Often prostate cancer is treated with the complex of the above-mentioned techniques or assumes their consecutive use, for example, surgery and hormonal treatment of prostate cancer together with radiation treatment. Clinical practice confirms that the combined approach shows the best results.
Also Check: Tooth Pain That Radiates To Ear